JACC Heart Failure · 2022 · 72 citations · 17 references
MedicinePharmacologyPharmacotherapyRenal PathophysiologyRenal PharmacotherapyRenal Replacement TherapyChronic Kidney DiseaseDiabetic NephropathyRenal DiseaseRenal Function TestsRenal ImpairmentRenal PharmacologyCardiorenal SyndromeCardiovascular Disease MortalityCkd ProgressionHeart Failure ProgressionImpaired Kidney FunctionKidney Function MonitoringMineralocorticoid Receptor AntagonismMineralocorticoid Receptor Pharmacology
BACKGROUND: In patients with type 2 diabetes (T2D), risks of cardiovascular mortality and heart failure (HF) increase with decreasing kidney function (estimated glomerular filtration rate [eGFR]) and increasing albuminuria (urine albumin-to-creatinine ratio [UACR]). Finerenone, a selective, nonsteroidal mineralocorticoid receptor antagonist, improved cardiorenal outcomes in patients with chronic kidney disease (CKD) and T2D in FIDELITY (Finerenone in Chronic Kidney Disease and Type 2 Diabetes: Combined FIDELIO-DKD and FIGARO-DKD Trial Programme Analysis). OBJECTIVES: This study sought to evaluate the effects of finerenone on HF outcomes by eGFR and/or UACR categories. METHODS: ) and/or UACR (<300 and ≥300 mg/g). RESULTS: and a UACR <300 mg/g. Finerenone improved HF outcomes irrespective of baseline eGFR and/or UACR categories (all P interaction values >0.10). CONCLUSIONS: Compared with placebo, finerenone improved HF-related outcomes in patients with CKD and T2D, with consistent benefits across eGFR and/or UACR categories. (Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease [FIDELIO-DKD], NCT02540993; Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Chronic Kidney Disease [FIGARO-DKD], NCT02545049).
17
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris, Rajiv Agarwal, Stefan D. Anker et al. · New England Journal of Medicine · 2020 · 2.6K citations · Full text